HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...
Clin Drug Invest. 2007;27(8):509-531. Antiretroviral drugs (ARVs) can be divided into four different classes according to their modes of action: nucleoside or nucleotide reverse transcriptase ...
Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells No significant financial relationships to disclose. This is an ASCO ...
(HealthDay News) — For treatment-naive patients infected with HIV-1, three nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens can attain similarly high rates of ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase ...
The Aicardi–Goutières syndrome is a genetic encephalopathy that is associated with childhood illness and death. The syndrome is hypothesized to be due to misidentification of self-derived nucleic ...
Despite the success of protease and reverse transcriptase inhibitors, new drugs to suppress HIV-1 replication are still needed. Several other early events in the viral life cycle (stages before the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results